Stock OVID OVID THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Ovid Therapeutics Inc.

Equities

OVID

US6904691010

Real-time Estimate Cboe BZX
Other stock markets
 12:43:37 2024-06-07 pm EDT 		5-day change 1st Jan Change
3.04 USD -1.94% Intraday chart for Ovid Therapeutics Inc. -0.33% -5.28%
May. 14 Earnings Flash (OVID) OVID THERAPEUTICS Posts Q1 Revenue $148,000 MT
May. 14 Ovid Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
GL
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
AQ
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
GL
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
GL
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus Post Grant Review
AQ
Ovid Therapeutics : Corporate Presentation
PU
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
GL
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
AQ
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
GL
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
AQ
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GL
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
AQ
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting
AQ
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
GL
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
AQ
Ovid Therapeutics : Corporate Presentation
PU
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
GL
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026
AQ
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
GL
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OVID Stock
  4. News Ovid Therapeutics Inc.
  5. Press Releases